#USA #New York #Class Action #Wolf Haldenstein #Gossamer Bio

Investors Seek Justice Against Gossamer Bio

In a recent development, Wolf Haldenstein Adler Freeman & Herz LLP has announced a class action lawsuit targeting Gossamer Bio, Inc. (NASDAQ: GOSS) on behalf of shareholders who suffered substantial financial losses. The lawsuit addresses issues surrounding the company's misleading public statements about their trials and performance.

Background

Between June 16, 2025, and February 20, 2026, Gossamer Bio misrepresented critical data concerning the efficacy of its clinical trials for seralutinib, a treatment for pulmonary arterial hypertension. Allegations suggest that the company crafted a narrative that did not align with the reality of their trial results, leading to uninformed financial decisions by investors. The essence of the lawsuit centers on accusations that Gossamer's leadership failed to disclose essential facts, resulting in an inflated stock value.

On February 23, 2026, the company revealed that its Phase 3 PROSERA study had not met its primary efficacy endpoint. The report pointed to a cohort of participants at Latin American sites who, due to their previously under-treated and lower risk status, showed unexpectedly favorable results on placebo. This revelation sent shockwaves through the market, causing Gossamer's shares to plummet from $2.13 to $0.42, an 80.3% decline in one day.

Class Action Details

The lawsuit is open to any investors who purchased Gossamer securities during the specified period. Interested parties have until June 1, 2026, to apply for the lead plaintiff position in the case. The filing highlights the need for transparency and accountability in corporate disclosures, especially when stakeholders' investments are at risk.

Wolf Haldenstein has a rich history of advocating for investor rights, boasting more than 125 years of legal expertise in securities litigation. Their dedication to addressing financial injustices and securing restitution for harmed investors is evident in the numerous successes they have achieved.

Why Choose Wolf Haldenstein?

This firm is committed to ensuring that those injured by misleading statements receive effective representation. Their vast experience positions them uniquely to navigate the complexities of securities class actions. Individuals affected by Gossamer Bio's actions are encouraged to reach out to the firm for a free consultation, with no obligations attached.

Contact Information

To get involved or acquire more information regarding the lawsuit, interested investors can contact: Gregory Stone, Director of Case and Financial Analysis by phone at (800) 575-0735 or (212) 545-4774, or through email at the firm's provided address. Their official website also provides further insights into their services and past cases.

This move by Wolf Haldenstein serves as a reminder of the importance of due diligence in the stock market and the essential role that legal accountability plays in protecting investor rights. Shareholders of Gossamer Bio must act swiftly, as the window for joining this pivotal lawsuit closes soon.

In summary, the Gossamer Bio incident underscores a growing trend where shareholders mobilize legal resources to combat corporate misconduct. For investors, the stakes have never been higher, and the legal landscape continues to evolve as they seek justice against deceptive business practices.